M13, an anthraquinone compound isolated from Morinda officinalis alleviates the progression of the osteoarthritis via the regulation of STAT3

作者：Baolin Zhang, Ya Xiao, Deying Su, Chuan Li, Shun Zhang, Jiahui Long, Ricong Weng, Hengyu Liu, Yingtong Chen, Zhiheng Liao, Xu Zhu, Junming Huang, Shuqing Chen, Taifeng Zhou, Yuan Ma, Caixia Xu · 发表于：Phytomedicine · 年份：2024 · DOI：10.1016/j.phymed.2024.156329 · 被引用次数：10 · 研究领域：Morinda citrifolia extract uses、Osteoarthritis Treatment and Mechanisms、Pain Mechanisms and Treatments

BACKGROUND: Osteoarthritis (OA) is characterized by the progressive deterioration of articular cartilage, leading to joint pain and functional impairment. OA severely impacts quality of life and presents a substantial societal burden. Currently, effective treatment options remain limited. Morinda officinalis (MO), a traditional Chinese herb, is commonly used to treat rheumatoid arthritis and alleviate joint pain. M13, an anthraquinone extracted from MO, has shown significant anti-inflammatory properties, making it a promising candidate for the treatment of OA. However, its role in inhibiting OA progression and the mechanisms involved remain poorly understood. PURPOSE: The objective of this study is to examine the impact of M13 on osteoarthritis and uncover the mechanisms. METHODS: The effects of M13 on OA were assessed using TNF-α induced chondrocyte models and mice with destabilization of the medial meniscus (DMM). Celecoxib was used as a positive control. We evaluated the expression of factors related to chondrocyte degeneration and inflammation through qRT-PCR, immunoblotting, and immunofluorescence. Chondrocyte viability was measured using CCK-8 assays, EdU staining, and flow cytometry. Molecular docking, molecular dynamics simulations and isothermal titration calorimetry (ITC) were performed to evaluate the binding efficacy of target proteins. Additionally, the therapeutic effects of M13 in OA mice were confirmed through in vivo experiments. RESULTS: In primary murine ch...